Page 170 - Drug Class Review

Page 115 of 205
Drug Effectiveness Review Project

placebo 74.6 53.6 NR 89.6% 19.7 Secondary Outcome Measures: ADAS-Cog 13; ADAS-Cog 11 responders (≥ 4 point improvement); Activities of daily living were significantly better in GAL group than in placebo group (DAD No significant differences in sleep quality between groups (PSQI: P = 0.929; NPI sleep score: P = No significant differences in behavioral symptoms between GAL and placebo (NPI mean change) GAL-treated patients showed significantly superior cognitive functions compared to placebo (ADAS-Cog 11: +1.6 points; P < 0.001; ADAS-Cog 13: P = 0.004)* Overall clin

Alzheimer classification: Mild-moderate

Groups similar at baseline: Yes

Health Outcome Measures: 0.929)
Authors and Year: Rockwood et al. 2001; Markowitz et al. 2003
galantamine 75.2 56.7 NR 90.0% 19.6 Primary Outcome Measures: ADAS-Cog 11; CIBIC-plus NPI; DAD; PSQI; NPI sleep score Timing of assessments: Baseline and months 1 and 3 score: +4.3 points; P = 0.004) Intermediate Outcome Measures: plus: P = 0.003)*

• • • • • •

Final Report Update 1 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: Other germane population qualities: Other medical conditions • MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs